1208243-50-8
Chemical Structure
Cibinetide
Synonym(s): ARA290
- CAS No.: 1208243-50-8
- Formula:C51H84N16O21
- Molecular Weight:1257.31
SMILES: O=C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@@H](CO)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC1)NC1=O
Biological Activity: Cibinetide (ARA290) is a non-hematopoietic Erythropoietin analog. Cibinetide selectively activates the EPOR/CD131 heteromer IRR without activating EPOR homodimers, and exerts neuroprotective effects through β-common receptor signaling. Cibinetide inhibits Cathepsin K/OSCAR/OC-STAMP/DC-STAMP/NFATC1, increases OPG and Alkaline phosphatase, and decreases CD115. Cibinetide modulates SIRT1/NF-κB/IL-1β signaling, reduces inflammatory infiltration and periapical bone loss, protects pancreatic islets, reduces IBMIR-related platelet consumption, and prolongs graft function. Cibinetide extends healthspan and attenuates age-related cardiac and body weight decline. Cibinetide can be used in research on cerebral ischemic stroke, sarcoidosis-associated small fiber neuropathy, and type 1 diabetes[1][2][3][4][5][6][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cibinetide | 99.96% | Cibinetide (ARA290) is a non-hematopoietic Erythropoietin analog. Cibinetide selectively activates the EPOR/CD131 heteromer IRR without activating EPOR homodimers, and exerts neuroprotective effects through β-common receptor signaling. Cibinetide inhibits Cathepsin K/OSCAR/OC-STAMP/DC-STAMP/NFATC1, increases OPG and Alkaline phosphatase, and decreases CD115. Cibinetide modulates SIRT1/NF-κB/IL-1β signaling, reduces inflammatory infiltration and periapical bone loss, protects pancreatic islets, reduces IBMIR-related platelet consumption, and prolongs graft function. Cibinetide extends healthspan and attenuates age-related cardiac and body weight decline. Cibinetide can be used in research on cerebral ischemic stroke, sarcoidosis-associated small fiber neuropathy, and type 1 diabetes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.74
HY-P11349TG-Gln -
Similarity Score 0.72
HY-P11565TANELNLLILR -
Similarity Score 0.72
HY-P10339SMCY peptide -
Similarity Score 0.72
![[Ala9,10, Lys11,12] Glycogen Synthase (1-12) Chemical Structure](//file.medchemexpress.com/product_pic/hy-p3741.gif)
HY-P3741[Ala9,10, Lys11,12] Glycogen Synthase (1-12) -
Similarity Score 0.71
HY-P10404PDpep1.3 -
Similarity Score 0.71
HY-P10849IP3RPEP6 -
Similarity Score 0.71
HY-P11566ISTLNSLTLPALR -
Similarity Score 0.71
HY-P11877PLSRTLSVAAK -
Similarity Score 0.70
HY-P11435KQSSKALQR -
Explore the MedChemAI to find more analogs
![[Ala9,10, Lys11,12] Glycogen Synthase (1-12) Chemical Structure](http://file.medchemexpress.com/product_pic/hy-p3741.gif)
References
- [1]. Awida Z, et al. The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International journal of molecular sciences. 2021 Dec 21;23(1):55. [Content Brief]
- [2]. Morrell C. ARA290, a small non-hematopoietic peptide derived from erythropoietin, prolongs healthspan and attenuates age-associated declines in cardiac function[J]. Journal of Molecular and Cellular Cardiology, 2018.
- [3]. Wang RL, et al. Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke. CNS neuroscience & therapeutics. 2024 Mar;30(3):e14676. [Content Brief]
- [4]. Liu X, et al. Apoevs Promote Diabetic Tooth Extraction Healing By Regulating Neutrophil Phenotype. International Dental Journal. 2025 Oct 1;75:106121.
- [5]. Gemignani F, et al. Non-length-dependent small fiber neuropathy: Not a matter of stockings and gloves. Muscle & nerve. 2022 Jan;65(1):10-28. [Content Brief]
- [6]. Yan LL, et al. The Influence of Microenvironment on Survival of Intraportal Transplanted Islets. Frontiers in immunology. 2022;13:849580.
- [7]. Yao M H. Targeting innate and adaptive immune responses to achieve long-term allograft acceptance following transplantation[D]. Karolinska Institutet (Sweden), 2022.
